Dateline City:
KENILWORTH, N.J.
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up
KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced final overall survival (OS) data from KEYNOTE-006 and
new findings from KEYNOTE-001, including updated response rates,
duration of response data and three-year OS data with KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in patients with
unresectable or metastatic melanoma.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more